Ustekinumab and vedolizumab influence on cardiovascular risk factors in patients with Inflammatory Bowel Disease

被引：0
|
作者：
Amiama Roig, C. [1 ]
Suarez Ferrer, C. [1 ]
Poza Cordon, J. [1 ]
Rueda Garcia, J. L. [1 ]
Sanchez Azofra, M. [1 ]
Martin Arranz, E. [1 ]
Gonzalez Diaz, I. [1 ]
Amor Costa, C. [1 ]
Garcia Ramirez, L. [2 ]
Martin Arranz, M. D. [1 ]
机构：
[1] La Paz Univ Hosp, Dept Gastroenterol & Hepatol, Madrid, Spain
[2] La Paz Univ Hosp, Hosp La Paz Inst Hlth Res IdiPAZ, Madrid, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.773
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P473
引用
收藏
页码：S462 / S463
页数：4
相关论文
共 50 条
  • [1] The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
    Choi, Myeong Geun
    Ye, Byong Duk
    Yang, Suk-Kyun
    Shim, Tae Sun
    Jo, Kyung-Wook
    Park, Sang Hyoung
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (14)
  • [2] Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease
    Livne-Margolin, M.
    Ling, D.
    Konyo, S. Attia
    Haj, O.
    Abitbol, C. M.
    Ben-Horin, S.
    Kopylov, U.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I429 - I430
  • [3] Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease
    Livne-Margolin, M.
    Ling, D.
    Konyo, S. Attia
    Haj, O.
    Abitbol, C. M.
    Ben-Horin, S.
    Kopylov, U.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I429 - I430
  • [4] Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease
    Roig, Clara Amiama
    Ferrer, Cristina Suarez
    Garcia, Jose Luis Rueda
    Cordon, Joaquin Poza
    Sanchez-Azofra, Maria
    Arranz, Eduardo Martin
    Diaz, Irene Gonzalez
    Costa, Carmen Amor
    Martin-Arranz, Maria Dolores
    [J]. GASTROENTEROLOGIA Y HEPATOLOGIA, 2023, 46 (02): : 109 - 115
  • [5] Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Vedolizumab or Ustekinumab
    Pang, Alice
    Hudesman, David P.
    Chang, Shannon
    Axelrad, Jordan E.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S379 - S379
  • [6] Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease
    Restellini, Sophie
    Khanna, Reena
    Afif, Waqqas
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 (10) : 2165 - 2172
  • [7] Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study
    Wils, Pauline
    Seksik, Philippe
    Stefanescu, Carmen
    Nancey, Stephane
    Allez, Matthieu
    de Chambrun, Guillaume Pineton
    Altwegg, Romain
    Gilletta, Cyrielle
    Vuitton, Lucine
    Viennot, Stephanie
    Serrero, Melanie
    Fumery, Mathurin
    Savoye, Guillaume
    Collins, Michael
    Goutorbe, Felix
    Brixi, Hedia
    Bouguen, Guillaume
    Tavernier, Noemie
    Boualit, Medina
    Amiot, Aurelien
    Abitbol, Vered
    Laharie, David
    Pariente, Benjamin
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (04) : 460 - 470
  • [8] Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?
    Alsoud, Dahham
    Vermeire, Severine
    Verstockt, Bram
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2020, 55 : 17 - 30
  • [9] Risk of New or Recurrent Cancer After Vedolizumab or Ustekinumab Exposure in Patients With Inflammatory Bowel Disease and Previous Cancer
    Zenger, Cameron
    Hong, Simon J.
    Pecoriello, Jillian
    Pang, Alice S.
    Vallely, Margaret
    Hudesman, David
    Chang, Shannon
    Axelrad, Jordan
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S460 - S460
  • [10] Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
    Barre, A.
    Colombel, J. -F.
    Ungaro, R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (07) : 896 - 905
12345